1. Tsuruoka M, Inoue J, Onishi Y, Ninomiya M, Kakazu E, Iwata T, Sano A, Sato K, Harigae H, Masamune A.Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Gastroenterol. 2021,Feb 12;15(1):178-187. doi: 10.1159/000512397
2. Maiko Abumiya, Naoto Takahashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy. Scientific reports 11(1). 6362 - 6362
3. Maiko Abumiya, Naoto Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Masatomo Miura.Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance. Journal of clinical pharmacy and therapeutics 46(1) 219 - 222
4. Fumiko Ito, Masatomo Miura, Yuki Fujioka, Maiko Abumiya, Takahiro Kobayashi, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi.The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.International journal of hematology. 113(1) 100 - 105
5. Kawashima M, Carreras J, Higuchi H, Kotaki R, Hoshina T, Kawai Y, Okuyama K , Suzuki N, Ando K, Nakayama M, Umezu S, Horie R, Katagiri K, Goyama S, Kitamura T, Yano S, Nakamura N, and Kotani A. Rapid upregulation of PD-L1/L2 was induced on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia, DOI: 10.1038/s41375-020-0737-9, 2020
6. Yahata T, Ibrahim AA, Hirano H, Muguruma Y, Naka K, Vaughan DE, Miyata T, and Ando K. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells. Haematologica, 2021;106:483-494 doi:10.3324/haematol.2019.230227, 2020
7. Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, Hibiki Akashi, Yoshiaki Ogawa, Hiroshi Kawada, and Kiyoshi Ando. Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myelom. Oncotarget, 2020
8. Kojima M, Carreras J, Kikuti YY, Miyaoka M, Kikuchi T, Amaki J, Sato A, Ogiya D, Ando K, Nakamura N. Dose-adjusted EPOCH-R does not improve CNS invasion risk for newly diagnosed MYC rearrangement diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13.PMID: 32404573
9. Suzuki R, Ando K, Successful treatment of therapy-related acute promyelocytic leukemia with all-trans-retinoic acid following epirubicin for hepatocellular carcinoma and docetaxel and pembrolizumab therapies for lung carcinoma: a triple malignancy case. Tokai J Exp Clin Med. Jul 20;45(2):92-96.PMID: 32602108, 2020
10. Yamamoto Y, Kakisaki M, Shimizu T, Carreras J, Chiba T, Chamoto K, Kagawa T, Aoki T, Nakamura N, Ando K, Kotani A. PD-L1 is induced on hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 upregulation by the anti-HBV drug Entecavir. International Immunology, 32, 519-531, 2020